Company: RCUS
Filing Date: 2025-10-31
Form Type: 424B5
Source: 0001193125-25-260836
Chunk: 7

Company: Arcus Biosciences, Inc.
Filing Date: 2025-10-31
Form: 424B5
Chunk 7
---
 or after approval, which could lead to the discontinuation of our clinical development programs, refusal by regulatory authorities to approve our investigational products or limitations on the use of our 
 investigational products or, if discovered following marketing approval, revocation of marketing authorizations or subsequent limitations on the use of our investigational products.                                                            |

| • |     | A key element of our strategy is the development of intra-portfolio combinations. If we are not successful in                                                                                                                                           
 discovering, developing and commercializing investigational products that take advantage of different mechanisms of action to achieve superior outcomes relative to the use of single agents or other combination therapies, our ability to achieve our 
 strategic objectives would be impaired.                                                                                                                                                                                                                 |

| • |     | Certain of our investigational products may require companion diagnostics in certain indications. Failure to                                                                                                                      
 successfully develop, validate and obtain regulatory clearance or approval for such tests could harm our product development strategy or prevent us from realizing the full commercial potential of our investigational products. |

| • |     | We expect to depend on our collaboration with Gilead for the research, development, manufacture and                                   
 commercialization of our investigational products. If this collaboration is not successful, our business could be adversely affected. |

| • |     | We rely on third parties to conduct our clinical trials and perform some of our research and preclinical studies.                                                                                                                                       
 If these third parties do not satisfactorily carry out their contractual duties or fail to meet expected deadlines, our development programs may be delayed or subject to increased costs, each of which may have an adverse effect on our business and 
 prospects.                                                                                                                                                                                                                                              |

| • |     | Even if we receive marketing approval, we may not be successful in commercializing our investigational products. |

| • |     | Even if we receive marketing approval for one or more of our investigational products, our commercial success is 
 dependent on obtaining coverage and reimbursement approval for a product from a                                  |

S-4

| government or other third-party payor, which coverage may be delayed or may not be sufficient to cover our costs. |

| • |     | Obtaining and maintaining regulatory approval of investigational products in one jurisdiction does not guarantee                                                                                                                                      
 that we will be able to obtain or maintain regulatory approval in any other jurisdiction. Even if our investigational products are approved by the U.S. Food and Drug Administration, they may never be approved or commercialized outside the United 
 States, which would limit our ability to realize their full market potential.